ReviewInternational journal of nanomedicine2026
Tumor Microenvironment-Responsive Nanoparticles for Pancreatic Cancer Imaging and Treatment.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early diagnosis and effective treatment of pancreatic cancer remain major clinical challenges, one of the most aggressive and lethal tumors. The tumor microenvironment (TME) in pancreatic cancer exhibits unique features, including high interstitial fluid pressure (IFP), abnormal blood vessels, hypoxia, acidosis, and excess reactive oxygen species (ROS), all favoring tumor progression and immunosuppression, meanwhile offsetting diagnostic efficiency and treatment efficacy. Thus, the TME of pancreatic cancer is considered as a target of profound theranostic significance. Nanoparticles (NPs) have shown a high profile in bio-imaging and targeted drug delivery. Here, we depicted the TME of pancreatic cancer and reviewed the designs and performances of TME-transforming NPs in the diagnosis and treatment of pancreatic cancer, as well as the obstacles to be overcome before their clinical translation. This review is expected to provide sparks for the early diagnosis and personalized treatment for pancreatic cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.